Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 186-188
10.1182/blood-2022-170381